[go: up one dir, main page]

DE60033809D1 - Inhibitoren von metalloproteinasen - Google Patents

Inhibitoren von metalloproteinasen

Info

Publication number
DE60033809D1
DE60033809D1 DE60033809T DE60033809T DE60033809D1 DE 60033809 D1 DE60033809 D1 DE 60033809D1 DE 60033809 T DE60033809 T DE 60033809T DE 60033809 T DE60033809 T DE 60033809T DE 60033809 D1 DE60033809 D1 DE 60033809D1
Authority
DE
Germany
Prior art keywords
inhibitors
metal proteinases
proteinases
metal
arylpiperazines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60033809T
Other languages
English (en)
Other versions
DE60033809T2 (de
Inventor
Howard Tucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE60033809D1 publication Critical patent/DE60033809D1/de
Publication of DE60033809T2 publication Critical patent/DE60033809T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
DE60033809T 1999-06-04 2000-05-31 Inhibitoren von metalloproteinasen Expired - Fee Related DE60033809T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99401350 1999-06-04
EP99401350 1999-06-04
PCT/GB2000/002085 WO2000075108A1 (en) 1999-06-04 2000-05-31 Inhibitors of metalloproteinases

Publications (2)

Publication Number Publication Date
DE60033809D1 true DE60033809D1 (de) 2007-04-19
DE60033809T2 DE60033809T2 (de) 2007-12-06

Family

ID=8241999

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60033809T Expired - Fee Related DE60033809T2 (de) 1999-06-04 2000-05-31 Inhibitoren von metalloproteinasen

Country Status (17)

Country Link
US (1) US6916817B1 (de)
EP (1) EP1187811B1 (de)
JP (1) JP2003501414A (de)
KR (1) KR20020005769A (de)
CN (1) CN1159295C (de)
AT (1) ATE356114T1 (de)
AU (1) AU773967B2 (de)
BR (1) BR0011339A (de)
CA (1) CA2374460A1 (de)
DE (1) DE60033809T2 (de)
ES (1) ES2281346T3 (de)
IL (1) IL146543A0 (de)
MX (1) MXPA01012322A (de)
NO (1) NO20015892L (de)
NZ (1) NZ515829A (de)
WO (1) WO2000075108A1 (de)
ZA (1) ZA200109675B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
WO2003022801A1 (en) 2001-09-07 2003-03-20 Kaken Pharmaceutical Co., Ltd. Reverse hydroxamic acid derivatives
SE0301922D0 (sv) * 2003-06-27 2003-06-27 Astrazeneca Ab Novel compounds
GB0427403D0 (en) * 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
HRP20110874T1 (hr) * 2005-10-26 2011-12-31 Merck Serono Sa Derivati sulfonamida i njihova uporaba za modulaciju metaloproteinaza
KR100673015B1 (ko) 2005-11-14 2007-01-24 삼성전자주식회사 캐패시터를 갖는 반도체 소자 및 그 형성 방법
GB0617367D0 (en) * 2006-09-02 2006-10-11 Astrazeneca Ab Novel process
WO2008147763A1 (en) * 2007-05-23 2008-12-04 Array Biopharma Inc. Mmp inhibitors and methods of use thereof
HK1251972A1 (zh) 2015-05-06 2019-05-10 The Regents Of The University Of California K-ras调节剂
MA50014A (fr) 2017-04-20 2020-07-08 Leidos Biomedical Res Inc Modulateurs de k-ras
TW202012371A (zh) * 2018-04-18 2020-04-01 美商德洛斯股份有限公司 具乙烯碸部分之k-ras調節劑
EP3860608A1 (de) 2018-10-04 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr-inhibitoren zur behandlung von keratosen
CN111117990B (zh) * 2020-02-26 2023-03-28 中国医科大学 一种抑制mmp9活性的多肽及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817822A (en) * 1994-06-24 1998-10-06 Novartis Corporation Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
EA002810B1 (ru) * 1997-01-23 2002-10-31 Ф.Хоффманн-Ля Рош Аг Сульфамидные ингибиторы металлопротеаз
WO1999002510A1 (en) 1997-07-10 1999-01-21 Pharmacia & Upjohn S.P.A. Matrix metalloproteinase inhibitors
ZA988967B (en) * 1997-10-03 2000-04-03 Du Pont Pharm Co Lactam metalloprotease inhibitors.
CN100402496C (zh) 1998-01-30 2008-07-16 达尔文发现有限公司 用作基质金属蛋白酶抑制剂的化合物
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds

Also Published As

Publication number Publication date
IL146543A0 (en) 2002-07-25
US6916817B1 (en) 2005-07-12
JP2003501414A (ja) 2003-01-14
BR0011339A (pt) 2002-03-19
DE60033809T2 (de) 2007-12-06
AU773967B2 (en) 2004-06-10
KR20020005769A (ko) 2002-01-17
EP1187811A1 (de) 2002-03-20
AU5090900A (en) 2000-12-28
CN1159295C (zh) 2004-07-28
NO20015892D0 (no) 2001-12-03
ZA200109675B (en) 2003-02-24
CA2374460A1 (en) 2000-12-14
MXPA01012322A (es) 2002-07-22
ATE356114T1 (de) 2007-03-15
ES2281346T3 (es) 2007-10-01
NO20015892L (no) 2001-12-19
NZ515829A (en) 2003-10-31
WO2000075108A1 (en) 2000-12-14
CN1390200A (zh) 2003-01-08
EP1187811B1 (de) 2007-03-07

Similar Documents

Publication Publication Date Title
TR200100605T2 (tr) Arilpiperazinler ve bunların metaloproteinaz inhibe edici maddeler (MMP) olarak kullanımı
DE69809187D1 (de) Metalloproteinase-Inhibitoren
BR0317715A (pt) Composições e processos de uso de collajolie
ATE348616T1 (de) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
ATE465146T1 (de) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
UY27972A1 (es) Derivados de hidantoína
ATE445400T1 (de) Hydantion-derivate als hemmer von matrix- metalloproteinasen
NO20025811L (no) Forbindelser som er effektive som beta-2-adrenoreseptor- agonister så vel som PDE4-inhibitorer
DE60218633D1 (de) Inhibitoren von cruzipain und anderen cysteinproteasen
DE60033809D1 (de) Inhibitoren von metalloproteinasen
ATE411287T1 (de) Neue metallproteinaseinhibitoren
MY128164A (en) Compounds
ATE260246T1 (de) Selektive inhibitoren des urokinase-plasminogen aktivators
NO20023951L (no) Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler
EA200301101A1 (ru) Производные пиперазина и их применение в качестве ингибиторов pde4
DE60202669D1 (de) 6-phenylbenzonaphthyidine
DK1204659T3 (da) Serotonerge benzofuraner
ATE403422T1 (de) Substituierte hydrazone als hemmer von cyclooxygenase-2
NO20024679D0 (no) Krystallinsk farmasöytikum
ATE348803T1 (de) Tryptase-inhibitoren
ATE486880T1 (de) Neue stromelysin inhibitoren
DK1358182T3 (da) Diazocin-derivater og anvendelsen deraf som tryptase-inhibitorer
UA33865A (uk) Дикалієва сіль n-сукцин - dl-триптофану, що має антиангінальну та антигіпоксантну дію
PL356931A1 (pl) Zastosowanie naturalnych związków mających aktywność przeciwnaczyniotwórczą

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee